Enrique Alfaro García

Dr. Enrique Alfaro García

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2021 in EMBO Reports
Verified
Journal Article
Open access
PDF file
EGEnrique Alfaro García
Enrique Alfaro García
PLPablo López-Jiménez
Pablo López-Jiménez
JGJosé González-Martínez
José González-Martínez
MMMarcos Malumbres
Marcos Malumbres
JSJose Ángel Suja
Jose Ángel Suja
Rocío GómezRocío Gómez
Rocío Gómez
Cell division requires the regulation of karyokinesis and cytokinesis, which includes an essential role of the achromatic spindle. Although the functions of centrosomes are well characterised in somatic cells, their role during vertebrate spermatogenesis remains elusive. We have studied the dynamics of the meiotic centrosomes in male mouse during both meiotic divisions. Results show that meiotic centrosomes duplicate twice: first duplication occurs in the leptotene/zygotene transition, while the second occurs in interkinesis. The maturation of duplicated centrosomes during the early stages of prophase I and II are followed by their separation and migration to opposite poles to form bipolar spindles I and II. The study of the genetic mouse model Plk1 (Δ/Δ) indicates a central role of Polo-like kinase 1 in pericentriolar matrix assembly, in centrosome maturation and migration, and in the formation of the bipolar spindles during spermatogenesis. In addition, in vitro inhibition of Polo-like kinase 1 and Aurora A in organotypic cultures of seminiferous tubules points out to a prominent role of both kinases in the regulation of the formation of meiotic bipolar spindles.

13 March 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
EGEnrique Alfaro García
Enrique Alfaro García
EGElena Díaz García
Elena Díaz García
STSARA GARCÍA TOVAR
SARA GARCÍA TOVAR
ELEster Zamarrón de Lucas
Ester Zamarrón de Lucas
AMAlberto Mangas Moro
Alberto Mangas Moro
CCCarolina Cubillos-Zapata
Carolina Cubillos-Zapata
Severe COVID-19 disease leads to hypoxemia, inflammation and lymphopenia. Viral infection induces cellular stress and causes the activation of the innate immune response. The ubiquitin-proteasome system (UPS) is highly implicated in viral immune response regulation. The main function of the proteasome is protein degradation in its active form, which recognises and binds to ubiquitylated proteins. Some proteasome subunits have been reported to be upregulated under hypoxic and hyperinflammatory conditions. Here, we conducted a prospective cohort study of COVID-19 patients (n = 44) and age-and sex-matched controls (n = 20). In this study, we suggested that hypoxia could induce the overexpression of certain genes encoding for subunits from the α and β core of the 20S proteasome and from regulatory particles (19S and 11S) in COVID-19 patients. Furthermore, the gene expression of proteasome subunits was associated with lymphocyte count reduction and positively correlated with inflammatory molecular and clinical markers. Given the importance of the proteasome in maintaining cellular homeostasis, including the regulation of the apoptotic and pyroptotic pathways, these results provide a potential link between COVID-19 complications and proteasome gene expression.

Verified
Journal Article
Open access
PDF file
EGElena Díaz García
Elena Díaz García
AGAldara Garcia-Sanchez
Aldara Garcia-Sanchez
DRDavid Sanz Rubio
David Sanz Rubio
EGEnrique Alfaro García
Enrique Alfaro García
CLCristina López-Fernández
Cristina López-Fernández
CCCarolina Cubillos-Zapata
Carolina Cubillos-Zapata
Obstructive sleep apnea (OSA) patients are at special risk of suffering atherosclerosis, leading to major cardiovascular diseases. Notably, the transforming growth factor (TGF-β) plays a crucial role in the development and progression of atherosclerosis. In this context, the central regulator of TGF-β pathway, SMAD4 (small mother against decapentaplegic homolog 4), has been previously reported to be augmented in OSA patients, which levels were even higher in patients with concomitant cardiometabolic diseases. Here, we analyzed soluble and intracellular SMAD4 levels in plasma and monocytes from OSA patients and non-apneic subjects, with or without early subclinical atherosclerosis (eSA). In addition, we used in vitro and ex vivo models to explore the mechanisms underlying SMAD4 upregulation and release. Our study confirmed elevated sSMAD4 levels in OSA patients and identified that its levels were even higher in those OSA patients with eSA. Moreover, we demonstrated that SMAD4 is overexpressed in OSA monocytes and that intermittent hypoxia contributes to SMAD4 upregulation and release in a process mediated by NLRP3. In conclusion, this study highlights the potential role of sSMAD4 as a biomarker for atherosclerosis risk in OSA patients and provides new insights into the mechanisms underlying its upregulation and release to the extracellular space.

Verified
Journal Article
Open access
PDF file
PBPilar Resano Barrio
Pilar Resano Barrio
EGEnrique Alfaro García
Enrique Alfaro García
ESEsther Solano-Pérez
Esther Solano-Pérez
CCCarlota Coso
Carlota Coso
CCCarolina Cubillos-Zapata
Carolina Cubillos-Zapata
ONOn Behalf Of The Spanish Sleep Network
On Behalf Of The Spanish Sleep Network
Obstructive sleep apnea (OSA) has been identified as a cardiovascular (CV) risk factor. The potential of OSA promoting the synthesis of CV biomarkers in acute coronary syndrome (ACS) is unknown. Ischemia-modified albumin (IMA) has been identified as a specific CV biomarker. The aim of this study was to evaluate the role of IMA as a potential biomarker for determining the impact of OSA in ACS patients. A total of 925 patients (15.5% women, age: 59 years, body mass index: 28.8 kg/m2) from the ISAACC study (NCT01335087) were included. During hospitalization for ACS, a sleep study for OSA diagnosis was performed and blood samples extraction for IMA determination were obtained. IMA values were significantly higher in severe OSA (median (IQR), 33.7 (17.2–60.3) U/L) and moderate (32.8 (16.9–58.8) U/L) than in mild/no OSA (27.7 (11.8–48.6) U/L) (p = 0.002). IMA levels were very weakly related to apnea–hypopnea index (AHI) as well as hospital and intensive care unit stay, although they only maintained a significant relationship with days of hospital stay after adjusting for sex, age and BMI (ß = 0.410, p = 0.013). The results of the present study would suggest a potentially weaker role of OSA in the synthesis of the CV risk biomarker IMA in patients with ACS than in primary prevention.

1 February 2021 in Gastroenterología y Hepatología
Verified
Journal Article
Open access
GHGonzalo Hijos-Mallada
Gonzalo Hijos-Mallada
DADaniel Abad
Daniel Abad
VLViviana Laredo
Viviana Laredo
EGEnrique Alfaro García
Enrique Alfaro García
PCPablo Cañamares
Pablo Cañamares
CHCarlos Sostres Homedes
Carlos Sostres Homedes

14 September 2024 in European Respiratory Journal
Verified
Conference Paper
Closed access
EGEnrique Alfaro García
Enrique Alfaro García
EDElena Díaz-García
Elena Díaz-García
SGSara García-Tovar
Sara García-Tovar
RGRaúl Galera
Raúl Galera
RCRaquel Casitas
Raquel Casitas
CZCarolina Cubillos Zapata
Carolina Cubillos Zapata
Understanding the respiratory consequences of severe COVID-19 is crucial for comprehensive patient care. This study aims to evaluate the impact of post-COVID conditions on respiratory sequelae of severe acute respiratory distress syndrome (ARDS). We examined 88 survivors of COVID-19-associated severe ARDS six months post-intensive care unit (ICU) discharge. Assessments included clinical and functional evaluation as well as plasma biomarkers of endothelial dysfunction, inflammation, and viral response. Additionally, an in vitro model using human umbilical vein endothelial cells (HUVECs) explored the direct impact of post-COVID plasma on endothelial function. Post-COVID patients with impaired gas exchange demonstrated persistent endothelial inflammation marked by elevated ICAM-1, IL-8, CCL-2, and ET-1 plasma levels. Concurrently, systemic inflammation, evidenced by NLRP3 overexpression and elevated levels of IL-6, TNF-α, and sCD40L, was associated with endothelial dysfunction biomarkers and increased in post-COVID patients with impaired gas exchange. T-cell activation, reflected in CD69 expression, and persistently elevated levels of IFN‑β further contributed to sustained inflammation. The in vitro model confirmed that patients’ plasma, with increased levels of sCD40-L and IFN-β proteins, alters endothelial function. In conclusion, six months post-ICU discharge, survivors of COVID-19-associated ARDS exhibit sustained elevation in endothelial dysfunction biomarkers, correlating with the severity of impaired gas exchange. NLRP3 inflammasome activity and persistent T-cell activation indicate on going inflammation contributing to persistent endothelial dysfunction.